<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Clin Cancer Res</journal-id><journal-title>Journal of Experimental &#x00026; Clinical Cancer Research : CR</journal-title><issn pub-type="ppub">0392-9078</issn><issn pub-type="epub">1756-9966</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1756-9966-28-22</article-id><article-id pub-id-type="pmid">19228369</article-id><article-id pub-id-type="doi">10.1186/1756-9966-28-22</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Combination of p53AIP1 and survivin expression is a powerful prognostic marker in non-small cell lung cancer</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Yamashita</surname><given-names>Shin-ichi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>yamashi1@med.oita-u.ac.jp</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Chujo</surname><given-names>Masao</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>chujo@med.oita-u.ac.jp</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Miyawaki</surname><given-names>Michiyo</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>miyawak@med.oita-u.ac.jp</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Tokuishi</surname><given-names>Keita</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>m207056@med.oita-u.ac.jp</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Anami</surname><given-names>Kentaro</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>k-anami@med.oita-u.ac.jp</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Yamamoto</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>s-yamamoto@med.oita-u.ac.jp</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Kawahara</surname><given-names>Katsunobu</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>kkawahar@med.oita-u.ac.jp</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Surgery II, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama, Yufu, Oita, 879-5593, Japan</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>19</day><month>2</month><year>2009</year></pub-date><volume>28</volume><issue>1</issue><fpage>22</fpage><lpage>22</lpage><ext-link ext-link-type="uri" xlink:href="http://www.jeccr.com/content/28/1/22"/><history><date date-type="received"><day>12</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>19</day><month>2</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Yamashita et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Yamashita et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Yamashita Shin-ichi yamashi1@med.oita-u.ac.jp </dc:author><dc:title> Combination of p53AIP1 and survivin expression is a powerful prognostic marker in non-small cell lung cancer </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Journal of Experimental &#x00026; Clinical Cancer Research 28(1): 22-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1756-9966(2009)28:1&#x0003c;22&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1756-9966</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>p53AIP1 is a potential mediator of apoptosis depending on p53, which is mutated in many kinds of carcinoma. High survivin expression in non-small cell lung cancer is related with poor prognosis. To investigate the role of these genes in non-small cell lung cancer, we compared the relationship between p53AIP1 or survivin gene expression and the clinicopathological status of lung cancer.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>Forty-seven samples from non-small cell lung cancer patients were obtained between 1997 and 2003. For quantitative evaluation of RNA expression by PCR, we used Taqman PCR methods.</p></sec><sec><title>Results</title><p>Although no correlation between p53AIP1 or survivin gene expression and clinicopathological factors was found, the relationship between survivin gene expression and nodal status was significant (p = 0.03). Overall survival in the p53AIP1-negative group was significantly worse than in the positive group (p = 0.04); however, although survivin expression was not a prognostic factor, the combination of p53AIP1 and survivin was a significant prognostic predictor (p = 0.04). In the multivariate cox proportional hazard model, the combination was an independent predictor of overall survival (p53AIP1 (+) survivin (+), HR 0.21, 95%CI = [0.01&#x02013;1.66]; p53AIP1 (+) survivin (-), HR 0.01, 95%CI = [0.002&#x02013;0.28]; p53AIP1 (-) survivin (-), HR 0.01, 95%CI = [0.002&#x02013;3.1], against p53AIP1 (-) survivin (+), p = 0.03).</p></sec><sec><title>Conclusion</title><p>These data suggest that the combination of p53AIP1 and survivin gene expression may be a powerful tool to stratify subgroups with better or worse prognosis from the variable non-small cell lung cancer population.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>A number of genes for apoptosis play an important role in tumorigenesis [<xref ref-type="bibr" rid="B1">1</xref>]. Several gene abnormalities were reported as prognostic markers of non-small cell lung cancer, such as p53 [<xref ref-type="bibr" rid="B2">2</xref>]; however, these processes are complex and remain unclear.</p><p>The abnormal expression of p53 is frequently reported in a variety of cancers [<xref ref-type="bibr" rid="B3">3</xref>]. p53 mutations are generally more common in smokers than in nonsmokers and an excess of G to T transversions of p53 has been described as a molecular signature of tobacco smoke mutagens in smoking-associated lung cancers. There are also mutational hotspots (codons 157, 158, 245, 248, and 273) in the p53 gene in lung cancer [<xref ref-type="bibr" rid="B4">4</xref>]. Several reports have shown that p53 expression is a prognostic marker in non-small cell lung cancer [<xref ref-type="bibr" rid="B2">2</xref>]. p53 protein is a tumor suppressor gene and mediates cell cycle arrest or programmed cell death [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. These p53-mediated events were triggered through the transactivation of specific genes, including p21, GADD45, cyclin G1, Bax, and fas [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>].</p><p>Recently, we reported that p53AIP1, which is a new potential mediator of p53-dependent apoptosis, is associated with prognosis in non-small cell lung cancer [<xref ref-type="bibr" rid="B9">9</xref>]. p53AIP1 is not normally expressed in any tissues except the thymus, but is induced when Ser-46 of p53 was phosphorylated after severe DNA damage [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Only a few papers have reported p53AIP1 function in cancer biology and it has not been well investigated [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B12">12</xref>].</p><p>On the other hand, survivin is a member of the <italic>IAP </italic>gene family, which has been implicated in both the inhibition of apoptosis and mitosis regulation [<xref ref-type="bibr" rid="B13">13</xref>]. Survivin up-regulates genes in tumor tissues [<xref ref-type="bibr" rid="B14">14</xref>]. High survivin expression in the primary tumor is related to poor prognosis in many cancer types [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B20">20</xref>]. As p53 leads to the repression of survivin expression [<xref ref-type="bibr" rid="B21">21</xref>], p53 AIP1 might act inversely against survivin in the same manner as p53. It is interesting to evaluate both the expression of the p53AIP1 gene and survivin in primary non-small cell lung cancer.</p><p>In this study, we demonstrated the expression of these genes in non-small cell lung cancer and normal lung tissue, and the combination of p53AIP1 with survivin may be a prognostic marker.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients and Samples</title><p>This study was approved by the Institutional Review Board of the National Hospital Organization Kumamoto Medical Center (Kumamoto, Japan) and all patients completed informed consent forms. Forty-seven operative samples from non-small cell lung cancer (NSCLC) patients were obtained at the National Hospital Organization Kumamoto Medical Center (Kumamoto, Japan) between May 1997 and September 2003. The samples were histologically diagnosed as primary non-small cell lung cancer according to the WHO classification. None of the cases had received radiation therapy or chemotherapy before surgery. Adjacent normal lung tissue was also taken from all cases. Tissue specimens were frozen immediately with RNA later&#x02122;(QIAGEN) and stored at -80&#x000b0;C until RNA extraction. RNA from tissue samples was prepared using TRIzol reagents (Invitrogen). To evaluate cigarette consumption, a smoking index (SI) was used: cigarette consumption per day multiplied by smoking years. Referring to this index, smokers were divided into 2 groups, heavy smokers with indices &#x02265; 400, and light smokers &#x0003c; 400.</p></sec><sec><title>Quantitative PCR analysis</title><p>For quantitative evaluation of the RNA expression by PCR, we used Taqman PCR methods (TaqMan<sup>&#x000ae; </sup>Gene Expression Assays; Applied Biosystems, Tokyo, Japan) as previously reported [<xref ref-type="bibr" rid="B22">22</xref>]. The p53AIP1 gene was amplified by the following primer set as follows, reverse: ggggacttctcaggtcgtgt, forward: tggacttcttcatgccccga.</p><p>The p53AIP1 gene internal probe was ttgcggtgcgagtcgtggaagtaa. Survivin was amplified by the following primer set: reverse: ggggacttctcaggtcgtgt, forward: tggacttctt catgccccga. The survivin internal probe was ttgcggtgcgagtcgtgg aagtaa.</p><p>PCR amplification condition were one cycle of 50&#x000b0;C, 2 min, and 95&#x000b0;C, 10 min followed by 50 cycles of 95&#x000b0;C, 15 sec and 60&#x000b0;C, 1 min. The measured value was calculated by comparative Ct methods [<xref ref-type="bibr" rid="B22">22</xref>] and GAPDH gene amplification was used as a control. All reactions were duplicated. The amounts of p53AIP1 and survivin mRNA were expressed as n-fold GAPDH mRNA and the levels were compared relative to adjacent normal lung tissues. A tumor/normal ratio of p53AIP1 and survivin mRNA expression greater than 1 was identified as a positive expression, and the others as negative.</p></sec><sec><title>Statistical analysis</title><p>All statistical analysis was performed using Stat View J5.0 (SAS Institute Inc.). Different variables of tumors and normal tissues were analyzed with the chi-square test or Fisher's exact test. Overall survival was analyzed using the Kaplan-Meier method and evaluated by the log-rank test. Significant differences were considered at p &#x0003c; 0.05. The cutoff point was also p &#x0003c; 0.05 for univariate and multivariate Cox proportional hazard model analysis.</p></sec></sec><sec><title>Results</title><p>p53AIP1 and survivin expression in primary non-small cell lung cancer (NSCLC) was evaluated by real-time RT-PCR. All 47 samples were studied with paired histopathologically normal lung tissues which were far from the tumor margin. Table <xref ref-type="table" rid="T1">1</xref> shows a correlation between the clinicopathological status and p53AIP1 and survivin gene expressions. Although no relationship between the p53AIP1 gene expression and variables (age, sex, smoking index (SI), tumor size, nodal status, histological type) was not found, the survivin gene expression-positive rates in the node metastasis-positive group were significantly higher than in the negative group (p = 0.03).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Correlation between p53AIP1 or survivin expression and clinicopathological characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Characteristics</td><td align="left" colspan="2">All patients</td><td align="left">p53AIP1 positive</td><td align="left">p</td><td align="left">Survivin positive</td><td align="left">p</td></tr></thead><tbody><tr><td align="left">Age</td><td align="left">&#x0003c;70</td><td align="left">19</td><td align="left">11</td><td></td><td align="left">14</td><td></td></tr><tr><td></td><td align="left">&#x02265;70</td><td align="left">28</td><td align="left">14</td><td align="left">0.23</td><td align="left">14</td><td align="left">0.45</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Sex</td><td align="left">male</td><td align="left">14</td><td align="left">6</td><td></td><td align="left">11</td><td></td></tr><tr><td></td><td align="left">female</td><td align="left">33</td><td align="left">19</td><td align="left">0.36</td><td align="left">17</td><td align="left">0.08</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Smoking</td><td align="left">&#x0003c;400</td><td align="left">19</td><td align="left">10</td><td></td><td align="left">13</td><td></td></tr><tr><td align="left">index</td><td align="left">&#x02265;400</td><td align="left">28</td><td align="left">15</td><td align="left">0.95</td><td align="left">15</td><td align="left">0.31</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Tumor</td><td align="left">T1</td><td align="left">27</td><td align="left">16</td><td></td><td align="left">18</td><td></td></tr><tr><td></td><td align="left">T2</td><td align="left">16</td><td align="left">9</td><td></td><td align="left">8</td><td></td></tr><tr><td></td><td align="left">T3</td><td align="left">4</td><td align="left">0</td><td align="left">0.08</td><td align="left">2</td><td align="left">0.52</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Nodal status</td><td align="left">N0</td><td align="left">33</td><td align="left">12</td><td></td><td align="left">10</td><td></td></tr><tr><td></td><td align="left">N1</td><td align="left">14</td><td align="left">5</td><td align="left">0.17</td><td align="left">9</td><td align="left">0.03*</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Histologic type</td><td align="left">Ad</td><td align="left">27</td><td align="left">12</td><td></td><td align="left">19</td><td></td></tr><tr><td></td><td align="left">Sq</td><td align="left">16</td><td align="left">10</td><td></td><td align="left">7</td><td></td></tr><tr><td></td><td align="left">others</td><td align="left">4</td><td align="left">3</td><td align="left">0.34</td><td align="left">2</td><td align="left">0.22</td></tr></tbody></table><table-wrap-foot><p>Ad, adenocarcinoma; Sq, squarmous cell carcinoma</p><p>* statistically significant</p></table-wrap-foot></table-wrap><p>Figure <xref ref-type="fig" rid="F1">1</xref> shows the overall survival curves by Kaplan-Meier analysis for patients with non-small cell lung cancer classified according to p53AIP1 expression (positive, tumor/normal ratio &#x02265; negative, &#x0003c;1). Patients in the positive p53AIP1 expression group have a better prognosis than the negative expression group (p = 0.04). The median follow-up period was 5.4 years (1.2 to 8.4 years); however, the superiority of the survivin expression negative group to the positive group for overall survival was not significant (Figure <xref ref-type="fig" rid="F2">2</xref>). When we compared the prognosis according to the variable combination between p53AIP1 and survivin, the p53AIP (+) survivin (-) group had the best prognosis (Figure <xref ref-type="fig" rid="F3">3</xref>). In contrast, the p53AIP (-) survivin (+) group showed the worst prognosis and the other two groups were intermediate. In univariate analysis using age, tumor size, lymph node metastasis, histological type, survivin expression, p53AIP1 expression, and the combination of p53AIP1 and survivin, p53AIP1 and the combination were statistically significant (Table <xref ref-type="table" rid="T2">2</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Overall survival curves according to p53AIP1 gene expression</bold>. Differences are significant (p = 0.04). Number of patients in each group, positive, 22; negative, 25.</p></caption><graphic xlink:href="1756-9966-28-22-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Overall survival curves according to survivin gene expression</bold>. Differences are not significant (p = 0.36. Number of patients in each group, positive, 28; negative, 19.</p></caption><graphic xlink:href="1756-9966-28-22-2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Overall survival curves according to the combination of p53AIP1 and survivin gene expression</bold>. Differences are statistically significant (p = 0.04). Number of patients in each group, p53AIP1 positive and survivin positive, 15; p53AIP1 positive and survivin negative, 9; p53AIP1 negative and survivin positive, 14; p53AIP1 negative and survivin negative, 9.</p></caption><graphic xlink:href="1756-9966-28-22-3"/></fig><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Clinicopathological factors and p53AIP1 or survivin expression for overall survival in univariate and multivariate Cox regression analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" colspan="2">Characteristics</td><td align="left" colspan="2">Univariate analysis</td><td align="left" colspan="2">Multivariate analysis</td></tr><tr><td></td><td></td><td align="left">HR (95%CI)</td><td align="left">p</td><td align="left">HR (95%CI)</td><td align="left">p</td></tr></thead><tbody><tr><td align="left">Age</td><td align="left">&#x0003c;70</td><td align="left">1</td><td align="left">0.55</td><td></td><td align="left">0.86</td></tr><tr><td></td><td align="left">&#x02265;70</td><td align="left">1.34 (0.52&#x02013;3.48)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Tumor</td><td align="left">T1</td><td align="left">1</td><td align="left">0.63</td><td></td><td align="left">0.93</td></tr><tr><td></td><td align="left">T2</td><td align="left">1.08 (0.14&#x02013;8.58)</td><td></td><td></td><td></td></tr><tr><td></td><td align="left">T3</td><td align="left">1.72 (0.21&#x02013;14.0)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Nodal status</td><td align="left">N0</td><td align="left">1</td><td align="left">0.47</td><td></td><td align="left">0.89</td></tr><tr><td></td><td align="left">N1</td><td align="left">1.46 (0.52&#x02013;4.17)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Histologic type</td><td align="left">Ad</td><td align="left">1</td><td align="left">0.23</td><td></td><td align="left">0.06</td></tr><tr><td></td><td align="left">Sq</td><td align="left">0.41 (0.11&#x02013;1.49)</td><td></td><td></td><td></td></tr><tr><td></td><td align="left">others</td><td align="left">0.28 (0.06&#x02013;1.25)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">survivin</td><td align="left">(+)</td><td align="left">1</td><td align="left">0.36</td><td></td><td align="left">0.19</td></tr><tr><td></td><td align="left">(-)</td><td align="left">0.62 (0.22&#x02013;1.75)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">p53AIP1</td><td align="left">(+)</td><td align="left">1</td><td align="left">0.04*</td><td></td><td align="left">0.48</td></tr><tr><td></td><td align="left">(-)</td><td align="left">2.67 (0.99&#x02013;7.25)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Combination</td><td></td><td></td><td align="left">0.04*</td><td></td><td align="left">0.03*</td></tr><tr><td align="left">p53AIP1 (-) survivin (+)</td><td></td><td align="left">1</td><td></td><td align="left">1</td><td></td></tr><tr><td align="left">p53AIP1 (+) survivin (+)</td><td></td><td align="left">0.31 (0.09&#x02013;1.0)</td><td></td><td align="left">0.21(0.01&#x02013;1.66)</td><td></td></tr><tr><td align="left">p53AIP1 (+) survivin (-)</td><td></td><td align="left">0.12 (0.02&#x02013;0.97)</td><td></td><td align="left">0.01 (0.002&#x02013;0.28)</td><td></td></tr><tr><td align="left">p53AIP1 (-) survivin (-)</td><td></td><td align="left">0.46(0.12&#x02013;1.7)</td><td></td><td align="left">0.01(0.002&#x02013;3.1)</td><td></td></tr></tbody></table><table-wrap-foot><p>Ad, adenocarcinoma; Sq, squarmous cell carcinoma</p><p>* statistically significant</p></table-wrap-foot></table-wrap><p>In multivariate Cox proportional hazard model analysis, the combination (p = 0.03) was an independent predictor of overall survival (Table <xref ref-type="table" rid="T2">2</xref>).</p></sec><sec><title>Discussion</title><p>The molecular mechanism of tumor progression and apoptosis is still unclear. Several predictors, such as nodal involvement, tumor stage, and survivin and p53 have been reported; however, the relationship between p53 or survivin and the prognosis of lung cancer patients is still controversial [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. As we recently reported, p53AIP1 in primary non-small cell lung caner has a potential role as a prognostic factor [<xref ref-type="bibr" rid="B9">9</xref>]. Additionally, the other report showed that truncating variants of P53AIP1 were associated with prostate cancer [<xref ref-type="bibr" rid="B12">12</xref>]. A recent report showed that p53AIP1 was directly regulated by not only p53 but p73 [<xref ref-type="bibr" rid="B24">24</xref>]. This might be supported by the result which did not show a correlation between p53 mutation and p53AIP1 expression [<xref ref-type="bibr" rid="B9">9</xref>], and it may be interesting to investigate the p73 expression with p53AIP1. The present study showed that p53AIP1 is not related to any clinicopathological factors, which is different from the report that p53AIP1 is closely related to nodal status in our previous study [<xref ref-type="bibr" rid="B9">9</xref>]. This might be due to different analysis methods, the frequency or quantification of expression levels. Although univariate analysis showed that p53AIP1, a proapoptotic gene, is a good predictor of overall survival despite no correlation with several factors, multivariate analysis did not show this because of the limited sample size.</p><p>On the other hand, as previously reported, survivin-positive expression correlated with more aggressive behavior and poorer prognosis [<xref ref-type="bibr" rid="B13">13</xref>]. Meta-analysis of the role of survivin showed that positive survivin might be a prognostic factor [<xref ref-type="bibr" rid="B23">23</xref>]. In our study, survivin is significantly related to the nodal status, which may suggest that survivin plays the key role in lymph node metastasis, as in the previous report [<xref ref-type="bibr" rid="B25">25</xref>]; however, survivin was not a significant prognostic factor in the present study. It is difficult to estimate the prognostic value of survivin because the power of this study was low due to the limited sample size; therefore, we considered the combination of biomarkers to be more powerful to show the prognostic value of survivin and p53 AIP1.</p><p>The rationale was as follows, since p53 leads to the repression of survivin expression, and apoptotic cells induced by p53 caused resistance to apoptosis when survivin was overexpressed [<xref ref-type="bibr" rid="B21">21</xref>], p53 AIP1 might have an inverse effect against survivin in the same manner as p53. Furthermore, as the relationship between survivin and p53AIP1 has not been investigated, we hypothesized that the combination analysis of survivin with p53AIP1 can be a powerful tool for risk stratification. The combination of negative p53AIP1 and positive survivin showed the worst prognosis, leading to the speculation that these two genes act in an opposite manner and are critical for tumor progression. Multivariate analysis showed that the combination of these genes was an independent predictor of survival. Furthermore, p53AIP1 and survivin expressions in non-small cell lung cancer cells before chemotherapy may contribute as independent predictors of the effect of chemotherapy, such as DNA-damaging agents.</p><p>In conclusion, although the sample size was small, our study demonstrated that the combination of survivin with p53AIP1 gene expression in non-small cell lung cancer is a possible independent prognostic factor. Further investigation of these combinations might show the prognostic significance of these genes in non-small cell lung cancer.</p></sec><sec><title>Abbreviations</title><p>RT-PCR: reverse transcription-PCR.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>Authors have made substantial contributions to conception and design (MC, MM, and SY), acquisition of data (KT and KA), analysis, interpretation of data, organizing study (SY), and supervision of research group (KK)</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This study was supported by a grant for National Hospital Clinical Research from the Ministry of Health, Labour and Welfare of Japan. We are grateful to Dr Yuji Onodera, BML Inc., for technical support and Ms. Yoko Miyanari, Department of Surgery II, Oita University Faculty of Medicine.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>CC</given-names></name><name><surname>Hollstein</surname><given-names>M</given-names></name></person-group><article-title>Clinical implications of the p53 tumor-suppressor gene</article-title><source>N Engl J Med</source><year>1993</year><volume>329</volume><fpage>1318</fpage><lpage>1327</lpage><pub-id pub-id-type="pmid">8413413</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199310283291807</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitsudomi</surname><given-names>T</given-names></name><name><surname>Hamajima</surname><given-names>N</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name></person-group><article-title>Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>4055</fpage><lpage>4063</lpage><pub-id pub-id-type="pmid">11051256</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname><given-names>RJ</given-names></name><name><surname>Thompson</surname><given-names>AM</given-names></name><name><surname>Hall</surname><given-names>PA</given-names></name><name><surname>Lane</surname><given-names>DP</given-names></name></person-group><article-title>The p53 tumour suppressor gene</article-title><source>Br J Surg</source><year>1998</year><volume>85</volume><fpage>1460</fpage><lpage>1467</lpage><pub-id pub-id-type="pmid">9823903</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2168.1998.00910.x</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pfeifer</surname><given-names>GP</given-names></name><name><surname>Denissenko</surname><given-names>MF</given-names></name><name><surname>Olivier</surname><given-names>M</given-names></name><name><surname>Tretyakova</surname><given-names>N</given-names></name><name><surname>Hecht</surname><given-names>SS</given-names></name><name><surname>Hainaut</surname><given-names>P</given-names></name></person-group><article-title>Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>7435</fpage><lpage>7451</lpage><pub-id pub-id-type="pmid">12379884</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1205803</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Lane</surname><given-names>D</given-names></name><name><surname>Levine</surname><given-names>AJ</given-names></name></person-group><article-title>Surfing the p53 network</article-title><source>Nature</source><year>2000</year><volume>408</volume><fpage>307</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">11099028</pub-id><pub-id pub-id-type="doi">10.1038/35042675</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sionov</surname><given-names>RV</given-names></name><name><surname>Haupt</surname><given-names>Y</given-names></name></person-group><article-title>The cellular response to p53: the decision between life and death</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>6145</fpage><lpage>6157</lpage><pub-id pub-id-type="pmid">10557106</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1203130</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asker</surname><given-names>C</given-names></name><name><surname>Wiman</surname><given-names>KG</given-names></name><name><surname>Selivanova</surname><given-names>G</given-names></name></person-group><article-title>p53-induced apoptosis as a safeguard against cancer</article-title><source>Biochem Biophys Res Commun</source><year>1999</year><volume>265</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10548481</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.1999.1446</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>S</given-names></name><name><surname>Vousden</surname><given-names>KH</given-names></name></person-group><article-title>Mechanisms of p53-mediated apoptosis</article-title><source>Cell Mol Life Sci</source><year>1999</year><volume>55</volume><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">10065149</pub-id><pub-id pub-id-type="doi">10.1007/s000180050267</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>SI</given-names></name><name><surname>Masuda</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Matsuzaki</surname><given-names>H</given-names></name><name><surname>Kurizaki</surname><given-names>T</given-names></name><name><surname>Haga</surname><given-names>Y</given-names></name><name><surname>Ikei</surname><given-names>S</given-names></name><name><surname>Miyawaki</surname><given-names>M</given-names></name><name><surname>Kawano</surname><given-names>Y</given-names></name><name><surname>Chujyo</surname><given-names>M</given-names></name><name><surname>Kawahara</surname><given-names>K</given-names></name></person-group><article-title>p53AIP1 expression can be a prognostic marker in non-small cell lung cancer</article-title><source>Clin Oncol (R Coll Radiol)</source><year>2008</year><volume>20</volume><issue>2</issue><fpage>148</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">17851056</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oda</surname><given-names>K</given-names></name><name><surname>Arakawa</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Matsuda</surname><given-names>K</given-names></name><name><surname>Tanikawa</surname><given-names>C</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Nishimori</surname><given-names>H</given-names></name><name><surname>Tamai</surname><given-names>K</given-names></name><name><surname>Tokino</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Taya</surname><given-names>Y</given-names></name></person-group><article-title>p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53</article-title><source>Cell</source><year>2000</year><volume>102</volume><fpage>849</fpage><lpage>862</lpage><pub-id pub-id-type="pmid">11030628</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)00073-8</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Taya</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Arakawa</surname><given-names>H</given-names></name></person-group><article-title>p53AIP1 regulates the mitochondrial apoptotic pathway</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>2883</fpage><lpage>2889</lpage><pub-id pub-id-type="pmid">12019168</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Taniguchi</surname><given-names>K</given-names></name><name><surname>Seelan</surname><given-names>RS</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zarfas</surname><given-names>KE</given-names></name><name><surname>McDonnell</surname><given-names>SK</given-names></name><name><surname>Qian</surname><given-names>C</given-names></name><name><surname>Pan</surname><given-names>K</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Shridhar</surname><given-names>V</given-names></name><name><surname>Couch</surname><given-names>FJ</given-names></name><name><surname>Tindall</surname><given-names>DJ</given-names></name><name><surname>Beebe-Dimmer</surname><given-names>JL</given-names></name><name><surname>Cooney</surname><given-names>KA</given-names></name><name><surname>Isaacs</surname><given-names>WB</given-names></name><name><surname>Jacobsen</surname><given-names>SJ</given-names></name><name><surname>Schaid</surname><given-names>DJ</given-names></name><name><surname>Thibodeau</surname><given-names>SN</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name></person-group><article-title>Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>10302</fpage><lpage>10307</lpage><pub-id pub-id-type="pmid">17079449</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-0638</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>Validating survivin as a cancer therapeutic target</article-title><source>Nat Rev Cancer</source><year>2003</year><volume>3</volume><fpage>46</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">12509766</pub-id><pub-id pub-id-type="doi">10.1038/nrc968</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Velculescu</surname><given-names>VE</given-names></name><name><surname>Madden</surname><given-names>SL</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Lash</surname><given-names>AE</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Rago</surname><given-names>C</given-names></name><name><surname>Lal</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>CJ</given-names></name><name><surname>Beaudry</surname><given-names>GA</given-names></name><name><surname>Ciriello</surname><given-names>KM</given-names></name><name><surname>Cook</surname><given-names>BP</given-names></name><name><surname>Dufault</surname><given-names>MR</given-names></name><name><surname>Ferguson</surname><given-names>AT</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>TC</given-names></name><name><surname>Hermeking</surname><given-names>H</given-names></name><name><surname>Hiraldo</surname><given-names>SK</given-names></name><name><surname>Hwang</surname><given-names>PM</given-names></name><name><surname>Lopez</surname><given-names>MA</given-names></name><name><surname>Luderer</surname><given-names>HF</given-names></name><name><surname>Mathews</surname><given-names>B</given-names></name><name><surname>Petroziello</surname><given-names>JM</given-names></name><name><surname>Polyak</surname><given-names>K</given-names></name><name><surname>Zawel</surname><given-names>L</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><article-title>Analysis of human transcriptomes</article-title><source>Nat Genet</source><year>1999</year><volume>32</volume><fpage>387</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">10581018</pub-id><pub-id pub-id-type="doi">10.1038/70487</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>H</given-names></name><name><surname>Altieri</surname><given-names>DC</given-names></name><name><surname>Lu</surname><given-names>CD</given-names></name><name><surname>Toyoda</surname><given-names>M</given-names></name><name><surname>Tenjo</surname><given-names>T</given-names></name><name><surname>Tanigawa</surname><given-names>N</given-names></name></person-group><article-title>Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>5071</fpage><lpage>5074</lpage><pub-id pub-id-type="pmid">9823313</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Monzo</surname><given-names>M</given-names></name><name><surname>Rosell</surname><given-names>R</given-names></name><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>Astudillo</surname><given-names>J</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>JJ</given-names></name><name><surname>Maestre</surname><given-names>J</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>C</given-names></name><name><surname>Font</surname><given-names>A</given-names></name><name><surname>Barnadas</surname><given-names>A</given-names></name><name><surname>Abad</surname><given-names>A</given-names></name></person-group><article-title>A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>2100</fpage><lpage>2104</lpage><pub-id pub-id-type="pmid">10561264</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ikeguchi</surname><given-names>M</given-names></name><name><surname>Hirooka</surname><given-names>Y</given-names></name><name><surname>Kaibara</surname><given-names>N</given-names></name></person-group><article-title>Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma</article-title><source>Cancer</source><year>2002</year><volume>95</volume><fpage>1938</fpage><lpage>1945</lpage><pub-id pub-id-type="pmid">12404288</pub-id><pub-id pub-id-type="doi">10.1002/cncr.10898</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ikeguchi</surname><given-names>M</given-names></name><name><surname>Kaibara</surname><given-names>N</given-names></name></person-group><article-title>Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma</article-title><source>Br J Cancer</source><year>2002</year><volume>87</volume><fpage>883</fpage><lpage>887</lpage><pub-id pub-id-type="pmid">12373603</pub-id><pub-id pub-id-type="doi">10.1038/sj.bjc.6600546</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodel</surname><given-names>F</given-names></name><name><surname>Hoffmann</surname><given-names>J</given-names></name><name><surname>Grabenbauer</surname><given-names>GG</given-names></name><name><surname>Papadopoulos</surname><given-names>T</given-names></name><name><surname>Weiss</surname><given-names>C</given-names></name><name><surname>G&#x000fc;nther</surname><given-names>K</given-names></name><name><surname>Schick</surname><given-names>C</given-names></name><name><surname>Sauer</surname><given-names>R</given-names></name><name><surname>R&#x000f6;del</surname><given-names>C</given-names></name></person-group><article-title>High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection</article-title><source>Strahlenther Onkol</source><year>2002</year><volume>178</volume><fpage>426</fpage><lpage>435</lpage><pub-id pub-id-type="pmid">12240548</pub-id><pub-id pub-id-type="doi">10.1007/s00066-002-1003-y</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Masuda</surname><given-names>Y</given-names></name><name><surname>Kurizaki</surname><given-names>T</given-names></name><name><surname>Haga</surname><given-names>Y</given-names></name><name><surname>Murayama</surname><given-names>T</given-names></name><name><surname>Ikei</surname><given-names>S</given-names></name><name><surname>Kamei</surname><given-names>M</given-names></name><name><surname>Takeno</surname><given-names>S</given-names></name><name><surname>Kawahara</surname><given-names>K</given-names></name></person-group><article-title>Survivin expression predicts early recurrence in early-stage breast cancer</article-title><source>Anticancer Res</source><year>2007</year><volume>27</volume><fpage>2803</fpage><lpage>2808</lpage><pub-id pub-id-type="pmid">17695451</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mirza</surname><given-names>A</given-names></name><name><surname>McGuirk</surname><given-names>M</given-names></name><name><surname>Hockenberry</surname><given-names>TN</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Ashar</surname><given-names>H</given-names></name><name><surname>Black</surname><given-names>S</given-names></name><name><surname>Wen</surname><given-names>SF</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Kirschmeier</surname><given-names>P</given-names></name><name><surname>Bishop</surname><given-names>WR</given-names></name><name><surname>Nielsen</surname><given-names>LL</given-names></name><name><surname>Pickett</surname><given-names>CB</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name></person-group><article-title>Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway</article-title><source>Oncogen</source><year>2002</year><volume>21</volume><fpage>2613</fpage><lpage>2622</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1205353</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aarskog</surname><given-names>NK</given-names></name><name><surname>Vedeler</surname><given-names>CA</given-names></name></person-group><article-title>Real-time quantitative polymerase chain reaction. A new method that detects both the peripheral myelin protein 22 duplication in Charcot-Marie-Tooth type 1A disease and the peripheral myelin protein 22 deletion in hereditary neuropathy with liability to pressure palsies</article-title><source>Hum Genet</source><year>2000</year><volume>107</volume><fpage>494</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">11140948</pub-id><pub-id pub-id-type="doi">10.1007/s004390000399</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>GN</given-names></name><name><surname>He</surname><given-names>WX</given-names></name><name><surname>Ding</surname><given-names>JA</given-names></name></person-group><article-title>The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures</article-title><source>Lung Cancer</source><year>2008</year><volume>61</volume><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">18192073</pub-id><pub-id pub-id-type="doi">10.1016/j.lungcan.2007.11.011</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Costanzo</surname><given-names>A</given-names></name><name><surname>Merlo</surname><given-names>P</given-names></name><name><surname>Pediconi</surname><given-names>N</given-names></name><name><surname>Fulco</surname><given-names>M</given-names></name><name><surname>Sartorelli</surname><given-names>V</given-names></name><name><surname>Cole</surname><given-names>PA</given-names></name><name><surname>Fontemaggi</surname><given-names>G</given-names></name><name><surname>Fanciulli</surname><given-names>M</given-names></name><name><surname>Schiltz</surname><given-names>L</given-names></name><name><surname>Blandino</surname><given-names>G</given-names></name><name><surname>Balsano</surname><given-names>C</given-names></name><name><surname>Levrero</surname><given-names>M</given-names></name></person-group><article-title>DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes</article-title><source>Mol Cell</source><year>2002</year><volume>9</volume><fpage>175</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">11804596</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(02)00431-8</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aky&#x000fc;rek</surname><given-names>N</given-names></name><name><surname>Memis</surname><given-names>L</given-names></name><name><surname>Ekinci</surname><given-names>O</given-names></name><name><surname>K&#x000f6;kt&#x000fc;rk</surname><given-names>N</given-names></name><name><surname>Ozt&#x000fc;rk</surname><given-names>C</given-names></name></person-group><article-title>Survivin expression in pre-invasive lesions and non-small cell lung carcinoma</article-title><source>Virchows Arch</source><year>2006</year><volume>449</volume><fpage>164</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">16810543</pub-id><pub-id pub-id-type="doi">10.1007/s00428-006-0239-9</pub-id></citation></ref></ref-list></back></article> 